BRAF抑制剂：甲状腺癌治疗经验及毒性综述
BRAF inhibitors: experience in thyroid cancer and general review of toxicity.
作者信息
Cabanillas M E, Patel A, Danysh B P, Dadu R, Kopetz S, Falchook G
机构信息
Department of Endocrine Neoplasia & Hormonal Disorders, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd. Unit 1461, Houston, TX, 77030, USA,
出版信息
Horm Cancer. 2015 Feb;6(1):21-36. doi: 10.1007/s12672-014-0207-9. Epub 2014 Dec 3.
Abstract
The US Food and Drug Administration-approved BRAF inhibitors, vemurafenib and dabrafenib, have demonstrated superior efficacy in patients with BRAF-mutant melanomas but have limited efficacy in BRAF-mutant colorectal cancer. Little is known at this time regarding BRAF inhibitors in thyroid cancer. Initial reports in patients with progressive, radioactive iodine-refractory BRAF-mutant papillary thyroid cancer suggest response rates of approximately 30-40%. In this review, we discuss BRAF inhibitors in the context of thyroid cancer, the toxicities associated with BRAF inhibitors, and the suggested management of those toxicities. The management of vemurafenib and dabrafenib toxicities is applicable across all tumor types and may serve as a practical guide to their use.
摘要
美国食品药品监督管理局批准的BRAF抑制剂维莫非尼和达拉非尼，已在BRAF突变型黑色素瘤患者中显示出卓越疗效，但在BRAF突变型结直肠癌中的疗效有限。目前关于BRAF抑制剂在甲状腺癌中的情况知之甚少。对进展性、放射性碘难治性BRAF突变型甲状腺乳头状癌患者的初步报告显示，缓解率约为30%-40%。在本综述中，我们讨论了甲状腺癌背景下的BRAF抑制剂、与BRAF抑制剂相关的毒性以及针对这些毒性的建议处理方法。维莫非尼和达拉非尼毒性的处理适用于所有肿瘤类型，可作为其使用的实用指南。
相似文献
1
BRAF inhibitors: experience in thyroid cancer and general review of toxicity.BRAF抑制剂：甲状腺癌治疗经验及毒性综述
Horm Cancer. 2015 Feb;6(1):21-36. doi: 10.1007/s12672-014-0207-9. Epub 2014 Dec 3.
2
BRAF as a target for cancer therapy.BRAF 作为癌症治疗的靶点。
Anticancer Agents Med Chem. 2011 Mar;11(3):285-95. doi: 10.2174/187152011795347469.
3
Vemurafenib Active in Iodine-Refractory Thyroid Cancer.维莫非尼在碘难治性甲状腺癌中有效。
Cancer Discov. 2016 Oct;6(10):OF4. doi: 10.1158/2159-8290.CD-NB2016-105. Epub 2016 Aug 23.
4
[Progress of anti-tumor study based on BRAF].基于BRAF的抗肿瘤研究进展
Yao Xue Xue Bao. 2012 Dec;47(12):1567-74.
5
Dabrafenib and trametinib, alone and in combination for BRAF-mutant metastatic melanoma.达拉非尼联合曲美替尼，或单药用于治疗 BRAF 突变型转移性黑色素瘤。
Clin Cancer Res. 2014 Apr 15;20(8):2035-43. doi: 10.1158/1078-0432.CCR-13-2054. Epub 2014 Feb 28.
6
BRAF inhibitor therapy for melanoma, thyroid and colorectal cancers: development of resistance and future prospects.BRAF抑制剂治疗黑色素瘤、甲状腺癌和结直肠癌：耐药性的产生及未来前景
Curr Cancer Drug Targets. 2014;14(2):128-43. doi: 10.2174/1568009614666140121150930.
7
B-Raf Inhibition in the Clinic: Present and Future.B-Raf 抑制在临床上的应用：现状与未来。
Annu Rev Med. 2016;67:29-43. doi: 10.1146/annurev-med-090514-030732.
8
BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.BRAF 抑制剂在甲状腺癌细胞中诱导 RAS 通路的反馈激活。
Int J Mol Sci. 2021 May 27;22(11):5744. doi: 10.3390/ijms22115744.
9
[Cellular and molecular mechanisms of carcinogenic side effects and resistance to BRAF inhibitors in metastatic melanoma with BRAFV600 mutation: state of the knowledge].[BRAFV600 突变转移性黑色素瘤中致癌副作用及对 BRAF 抑制剂耐药的细胞与分子机制：知识现状]
Ann Pathol. 2013 Dec;33(6):375-85. doi: 10.1016/j.annpat.2013.09.003. Epub 2013 Oct 31.
10
Vemurafenib for the treatment of BRAF mutant metastatic melanoma.维莫非尼用于治疗BRAF突变转移性黑色素瘤。
Future Oncol. 2015;11(4):579-89. doi: 10.2217/fon.14.252.
引用本文的文献
1
Combination of astragalus polysaccharide with Diosbulbin B exerts an enhanced antitumor effect in BRAF papillary thyroid cancer with decreased liver toxicity.黄芪多糖与薯蓣皂苷元B联合应用对BRAF乳头状甲状腺癌具有增强的抗肿瘤作用，并降低肝毒性。
Cancer Cell Int. 2025 Jul 2;25(1):245. doi: 10.1186/s12935-025-03853-4.
2
Deciphering the role of Hashimoto's Thyroiditis-related key genes in thyroid cancer via detailed in silico analysis followed by the experimental validation.通过详细的计算机模拟分析，随后进行实验验证，来阐明桥本甲状腺炎相关关键基因在甲状腺癌中的作用。
Hereditas. 2025 May 31;162(1):91. doi: 10.1186/s41065-025-00429-0.
3
Potential application of [F]AlF-PSMA-11 PET/CT in radioiodine refractory thyroid carcinoma.[F]AlF-PSMA-11正电子发射断层显像/计算机断层扫描（PET/CT）在放射性碘难治性甲状腺癌中的潜在应用
EJNMMI Res. 2024 Sep 12;14(1):82. doi: 10.1186/s13550-024-01148-9.
4
Targeting NG2 relieves the resistance of BRAF-mutant thyroid cancer cells to BRAF inhibitors.靶向 NG2 可减轻 BRAF 突变型甲状腺癌细胞对 BRAF 抑制剂的耐药性。
Cell Mol Life Sci. 2024 May 25;81(1):238. doi: 10.1007/s00018-024-05280-6.
5
Advances in targeted therapy and biomarker research in thyroid cancer.甲状腺癌的靶向治疗和生物标志物研究进展。
Front Endocrinol (Lausanne). 2024 Mar 4;15:1372553. doi: 10.3389/fendo.2024.1372553. eCollection 2024.
6
Low-Grade Gliomas: Histological Subtypes, Molecular Mechanisms, and Treatment Strategies.低级别胶质瘤：组织学亚型、分子机制及治疗策略
Brain Sci. 2023 Dec 9;13(12):1700. doi: 10.3390/brainsci13121700.
7
Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment.小儿低级别胶质瘤靶向治疗期间及治疗后的综合反应分析
Neurooncol Adv. 2022 Dec 18;5(1):vdac182. doi: 10.1093/noajnl/vdac182. eCollection 2023 Jan-Dec.
8
Construction of a Tumor Immune Microenvironment-Related Prognostic Model in BRAF-Mutated Papillary Thyroid Cancer.构建 BRAF 突变型甲状腺乳头状癌肿瘤免疫微环境相关预后模型。
Front Endocrinol (Lausanne). 2022 Jun 8;13:895428. doi: 10.3389/fendo.2022.895428. eCollection 2022.
9
PRDM16 Inhibits Cell Proliferation and Migration via Epithelial-to-Mesenchymal Transition by Directly Targeting Pyruvate Carboxylase in Papillary Thyroid Cancer.PRDM16通过直接靶向甲状腺乳头状癌中的丙酮酸羧化酶，经由上皮-间质转化抑制细胞增殖和迁移。
Front Cell Dev Biol. 2021 Nov 2;9:723777. doi: 10.3389/fcell.2021.723777. eCollection 2021.
10
Alterations Induce Acquired Dabrafenib Resistance in Association with Anaplastic Transformation in a Papillary Thyroid Cancer Patient.在一名甲状腺乳头状癌患者中，改变诱导获得性达拉非尼耐药并伴有间变性转化。
Cancers (Basel). 2021 Sep 30;13(19):4950. doi: 10.3390/cancers13194950.
本文引用的文献
1
Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors.致癌基因模拟作为对BRAF抑制剂原发性耐药的一种机制。
Cell Rep. 2014 Aug 21;8(4):1037-48. doi: 10.1016/j.celrep.2014.07.010. Epub 2014 Aug 7.
2
Dimerization of the kinase ARAF promotes MAPK pathway activation and cell migration.激酶ARAF的二聚化促进丝裂原活化蛋白激酶（MAPK）信号通路的激活和细胞迁移。
Sci Signal. 2014 Aug 5;7(337):ra73. doi: 10.1126/scisignal.2005484.
3
Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors.达拉非尼的发现：一种对B-Raf驱动的肿瘤具有抗肿瘤活性的Raf激酶选择性抑制剂。
ACS Med Chem Lett. 2013 Feb 7;4(3):358-62. doi: 10.1021/ml4000063. eCollection 2013 Mar 14.
4
Acute Radiation Skin Toxicity Associated With BRAF Inhibitors.与BRAF抑制剂相关的急性放射性皮肤毒性
J Clin Oncol. 2016 Jan 20;34(3):e17-20. doi: 10.1200/JCO.2013.49.0565. Epub 2014 May 27.
5
Time to re-consider the meaning of BRAF V600E mutation in papillary thyroid carcinoma.是时候重新审视BRAF V600E突变在甲状腺乳头状癌中的意义了。
Int J Cancer. 2015 Sep 1;137(5):1001-11. doi: 10.1002/ijc.28976. Epub 2014 May 27.
6
New RAS-mutant pancreatic adenocarcinoma with combined BRAF and MEK inhibition for metastatic melanoma.新的RAS突变型胰腺腺癌联合BRAF和MEK抑制剂治疗转移性黑色素瘤。
J Clin Oncol. 2015 Apr 10;33(11):e52-6. doi: 10.1200/JCO.2013.51.5783. Epub 2014 May 12.
7
Vemurafenib-related cutaneous side effects ameliorated by acitretin.阿维A改善维莫非尼相关的皮肤副作用。
J Drugs Dermatol. 2014 May;13(5):586-8.
8
Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.索拉非尼用于放射性碘难治性、局部晚期或转移性分化型甲状腺癌：一项随机、双盲、3期试验。
Lancet. 2014 Jul 26;384(9940):319-28. doi: 10.1016/S0140-6736(14)60421-9. Epub 2014 Apr 24.
9
Radiation recall dermatitis and radiation pneumonitis during treatment with vemurafenib.维莫非尼治疗期间的放射性回忆性皮炎和放射性肺炎。
Melanoma Res. 2014 Oct;24(5):512-6. doi: 10.1097/CMR.0000000000000078.
10
Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.一名接受维罗非尼治疗的黑色素瘤患者面部和躯干出现多个白色囊肿。
Acta Derm Venereol. 2015 Jan;95(1):96-7. doi: 10.2340/00015555-1869.
Zotero 插件